Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of lenalidomide in a patient with systemic mastocytosis associated with SF3B1-mutant myelodysplastic syndrome.

Leukemia & lymphoma - 1 Dec 2021

Sarmiento Marcela, Rocca Gabriela S, Rahhal Marilina, Lincango Yupanki Marco, Zubieta Martín, Metrebian Fernanda, Narbaitz Marina, Larripa Irene B, Belli Carolina B

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lenalidomide
Share to Mastocytosis, Systemic
Share to Mutation
Share to Myelodysplastic Syndromes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phosphoproteins

Share to RNA Splicing Factors

Source

Identifiers

PMID: 34151705
DOI: 10.1080/10428194.2021.1941925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of lenalidomide in a patient with systemic mastocytosis associated with SF3B1-mutant myelodysplastic syndrome.PMID 34151705Read ↗

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studySemantic proximity Read ↗

Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyondSemantic proximity Read ↗

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.Semantic proximity Read ↗

Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Semantic proximity Read ↗

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionSemantic proximity Read ↗

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.Semantic proximity Read ↗

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesSemantic proximity Read ↗

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Semantic proximity Read ↗

A phase-2 trial of low-dose pomalidomide in myelofibrosis.Semantic proximity Read ↗

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read ↗

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.Semantic proximity Read ↗

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.